This is old, just a follow up, aptamers
Martinsried, Germany, December 05, 2003 - Bio-M AG announced that Archemix
Corp., a US-based biopharmaceutical company committed to the discovery and development of
aptamer therapeutics, has made an additional investment in the Bio-M portfolio company
NascaCell IP GmbH (Tutzing, Germany). Archemix Corp. has already participated in a financing round earlier this year. The proceeds will be used to strengthen NascaCell's market position in aptamer-based target validation and drug
discovery. Financial terms were not disclosed.
For more information about NascaCell IP please see www.nascacell.com.
Nascacell and DPI
nascacell.com
The only other trivia for the day is that Holtzman is
a director of Archemix
archemix.com
Regarding Holtzman, here is some old stuff from
the google cache, sorry, the PPT is gone.
72.14.203.104
There are a few fun tidbits that probably reflect
surplus hubris as infinity started up and was
selling itself to investors. But I will paste this
and ask what is "broad FTO"?
Infiniplex Chemistry
Novel classes of pharmaceutically relevant structures with broad FTO
Designed to be produced, optimized, and scaled rapidly
Pursue only highly validated targets
Open world of well-validated but “non-druggable” targets with Infiniplex chemistry
Use chemical genetic screening to let underlying disease biology find truly validated targets and establish utility for compound classes
InfiNet Knowledge Platform
Web-services based XML architecture
Implementation of meta-data models for knowledge management
IP asset development and audit control |
